These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

83 related articles for article (PubMed ID: 11695332)

  • 1. The role of gender in HIV progression.
    Hewitt RG; Parsa N; Gugino L
    BETA; 2001; 14(1):13-6. PubMed ID: 11695332
    [No Abstract]   [Full Text] [Related]  

  • 2. Women's health. The role of gender in HIV progression.
    Hewitt RG; Parsa N; Gugino L
    AIDS Read; 2001 Jan; 11(1):29-33. PubMed ID: 11215085
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treating HIV infection and AIDS in women.
    Squires KE
    AIDS Read; 2003 May; 13(5):228-34, 239-40. PubMed ID: 12800826
    [No Abstract]   [Full Text] [Related]  

  • 4. The women's interagency HIV study (WIHS): research findings.
    Hughes M
    Surviv News (Atlanta Ga); 2002 Mar; ():1. PubMed ID: 11966185
    [No Abstract]   [Full Text] [Related]  

  • 5. Issues in antiretroviral therapy: when to start?
    Boyle BA
    AIDS Read; 2001 Feb; 11(2):66-70. PubMed ID: 11279874
    [No Abstract]   [Full Text] [Related]  

  • 6. Compliance with antiretroviral regimens.
    Laurence J
    AIDS Read; 2001 Apr; 11(4):177, 181. PubMed ID: 11392675
    [No Abstract]   [Full Text] [Related]  

  • 7. Gender difference in viral load.
    Proj Inf Perspect; 1999 Apr; (27):18-9. PubMed ID: 11366734
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Determinants of clinical progression in antiretroviral-naive HIV-infected patients starting highly active antiretroviral therapy. Aquitaine Cohort, France, 1996-2002.
    Bonnet F; Thiébaut R; Chêne G; Neau D; Pellegrin JL; Mercié P; Beylot J; Dabis F; Salamon R; Morlat P;
    HIV Med; 2005 May; 6(3):198-205. PubMed ID: 15876287
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunological changes during treatment interruptions: risk factors and clinical sequelae.
    Poulton MB; Sabin CA; Fisher M
    AIDS; 2003 Jan; 17(1):126-8. PubMed ID: 12478080
    [No Abstract]   [Full Text] [Related]  

  • 10. Women & HIV. Lessons learned from natural history studies in women.
    Hanna L
    BETA; 2001; 13(4):22-30. PubMed ID: 11693077
    [No Abstract]   [Full Text] [Related]  

  • 11. HIV-1 viral rebound dynamics after a single treatment interruption depends on time of initiation of highly active antiretroviral therapy.
    Steingrover R; Pogány K; Fernandez Garcia E; Jurriaans S; Brinkman K; Schuitemaker H; Miedema F; Lange JM; Prins JM
    AIDS; 2008 Aug; 22(13):1583-8. PubMed ID: 18670217
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CD4 lymphocyte percentage versus absolute CD4 lymphocyte count in predicting HIV disease progression: an old debate revisited.
    Goicoechea M; Haubrich R
    J Infect Dis; 2005 Sep; 192(6):945-7. PubMed ID: 16107944
    [No Abstract]   [Full Text] [Related]  

  • 13. The role of non-viral load surrogate markers in HIV-positive patient monitoring during antiviral treatment.
    Florence E; Dreezen C; Schrooten W; Van Esbroeck M; Kestens L; Fransen K; De Roo A; Colebunders R
    Int J STD AIDS; 2004 Aug; 15(8):538-42. PubMed ID: 15307965
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predictive factors for immunological and virological endpoints in Thai patients receiving combination antiretroviral treatment.
    Srasuebkul P; Ungsedhapand C; Ruxrungtham K; Boyd MA; Phanuphak P; Cooper DA; Law MG
    HIV Med; 2007 Jan; 8(1):46-54. PubMed ID: 17305932
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Initial plasma HIV-1 RNA levels and progression to AIDS in women and men.
    Sterling TR; Vlahov D; Astemborski J; Hoover DR; Margolick JB; Quinn TC
    N Engl J Med; 2001 Mar; 344(10):720-5. PubMed ID: 11236775
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ongoing changes in HIV RNA levels during untreated HIV infection: implications for CD4 cell count depletion.
    Phillips AN; Lampe FC; Smith CJ; Geretti AM; Rodger A; Lodwick RK; Cambiano V; Tsintas R; Johnson MA
    AIDS; 2010 Jun; 24(10):1561-7. PubMed ID: 20505495
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Non-adherence to highly active antiretroviral therapy predicts progression to AIDS.
    Bangsberg DR; Perry S; Charlebois ED; Clark RA; Roberston M; Zolopa AR; Moss A
    AIDS; 2001 Jun; 15(9):1181-3. PubMed ID: 11416722
    [No Abstract]   [Full Text] [Related]  

  • 18. Characterization of immunologic and virological parameters in HIV-infected patients with primary effusion lymphoma during antiblastic therapy and highly active antiretroviral therapy.
    Simonelli C; Tedeschi R; Gloghini A; Bortolin MT; Spina M; Bidoli E; Cinelli R; De Paoli P; Carbone A; Tirelli U
    Clin Infect Dis; 2005 Apr; 40(7):1022-7. PubMed ID: 15824995
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The feminization of an epidemic. Women and HIV in the United States.
    Iobst S; Gandhi M
    Posit Aware; 2009; 20(4):34-9. PubMed ID: 19653375
    [No Abstract]   [Full Text] [Related]  

  • 20. Antiretroviral therapy interruption guided by CD4 cell counts and plasma HIV-1 RNA levels in chronically HIV-1-infected patients.
    Ruiz L; Paredes R; Gómez G; Romeu J; Domingo P; Pérez-Alvarez N; Tambussi G; Llibre JM; Martínez-Picado J; Vidal F; Fumaz CR; Clotet B;
    AIDS; 2007 Jan; 21(2):169-78. PubMed ID: 17197807
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.